Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Medicenna Therapeutics Corp ( (TSE:MDNA)) ...

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target ...

Four presentations highlight 12-month clinical outcomes, as well as MRI-assessed joint protection and patient perspectives supporting the SetPoint System as first-of-its-kind treatment for rheumatoid ...

ATLANTA - Pfizer Inc. (NYSE:PFE), a prominent player in the pharmaceuticals industry with a market cap of $141 billion and an impressive gross profit margin of 74%, will present research from 46 ...

Guardant Health (GH) announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American ...

The closure has shut off the flow of key economic data at a moment of uncertainty among policymakers and investors about the health of the US job market, the trajectory of inflation and the strength ...

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- ...

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie (ABBV)'s growing ADC portfolio designed to target ...

BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields ...

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from ...

DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections ...

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ...